IMMUNIC, INC. - 8-K Filing
Immunic announced the presentation of three posters at the CMSC Annual Meeting, including a late-breaking poster introducing new statistical analyses for assessing disability changes in progressive multiple sclerosis (PMS) from its phase 2 CALLIPER trial. Additional data highlighted vidofludimus calcium's favorable safety profile and no negative impact on mood over up to 120 weeks of treatment. (Items: 7.01 Regulation FD Disclosure On May 28, 2026, Immunic, Inc, 9.01 Financial Statements and Exhibits)
Tickers: $IMUX